Navigation Links
Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease
Date:3/8/2011

CRANBURY, N.J., March 8, 2011 /PRNewswire/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold for the AT2220 (1-deoxynojirimycin HCI) Investigational New Drug Application (IND).  AT2220 is a pharmacological chaperone in development as a treatment for Pompe disease.  Based on data provided by Amicus, the FDA agreed with the Company's proposal to resume clinical development of AT2220, starting with a new Phase 2 study designed to evaluate the use of AT2220 when co-administered with enzyme replacement therapy (ERT) in subjects with Pompe disease.  The Company expects to commence this study in the first half of 2011 and to report preliminary results in the second half of 2011.

Co-administration of Pharmacological Chaperones with ERTAmicus previously reported promising preclinical data demonstrating that the co-administration of a pharmacological chaperone with ERT has the potential to address key limitations of ERT. The addition of a pharmacological chaperone has been shown to prevent the loss of activity of ERT in the circulation, increase tissue uptake, and increase substrate reduction in multiple disease-relevant tissues. Preclinical proof of concept has been established for Fabry disease and Pompe disease.

About AT2220Data from Phase 1 studies in 72 healthy volunteers demonstrated that AT2220 was generally safe and well tolerated at all doses evaluated with no drug-related serious adverse events. Based on these data and encouraging safety data from preclinical studies, Amicus initiated a Phase 2 clinical trial of AT2220 as a monotherapy treatment in adults with Pompe disease.  The protocol involved initial treatment with a high dose of AT2220.  Two patients enrolled in the trial experienced adverse events categorized as serious and probably related to treat
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal™ Co-administered with Enzyme Replacement Therapy
2. Amicus Therapeutics to Present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2011
3. Amicus Therapeutics Awarded $500,000 Grant from The Michael J. Fox Foundation for Development of Next-Generation Pharmacological Chaperone to Treat Parkinsons Disease
4. Amicus Therapeutics Announces Third Quarter 2010 Financial Results
5. GSK and Amicus Therapeutics Enter Exclusive Worldwide Agreement to Develop and Commercialize Amigal™ for Fabry Disease
6. Amicus Therapeutics to Host Conference Call and Webcast to Discuss Exclusive Worldwide Agreement with GSK to Develop and Commercialize Amigal™ for Fabry Disease
7. Amicus Therapeutics to Host Its Second Quarter 2010 Financial Results Conference Call and Webcast on August 5, 2010
8. Amicus CEO Represents BIO on Rare Diseases at U.S. Senate Committee on Health, Education, Labor and Pensions Bipartisan Hearing
9. Alzheimers Drug Discovery Foundation Funds Amicus Therapeutics To Advance Pharmacological Chaperone Technology
10. Fenwal Receives FDA Clearance for Amicus(R) Separator With Wireless Connectivity
11. Amicus Therapeutics to Host its First Quarter 2010 Financial Results Conference Call and Webcast on May 6, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North America,s ... of high-value chemistry, will hold the 30 th edition ... Convention Center from January 21-24. (Logo: ... from top pharmaceutical, fine chemical and specialty chemical companies will ...
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new ... targeting guide with accompanying instrumentation to place and insert ... to the soft tissue (e.g. ligament) repair or reconstruction ... repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
(Date:1/14/2014)... CLEVELAND , Jan. 14, 2014 NineSigma ... will hold its Innovation Leadership Summit , May ... in Cleveland Ohio . ... innovators and organizations committed to breakthrough achievements through open ...
Breaking Medicine Technology:Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4
... Inc. (Nasdaq: PDII ) today announced that ... to enable eDetail delivery on popular mobile devices including ... iPhone ® (1) and Android™(2)-based phones. "With ... than the general population, we are moving quickly to ...
... STAAR Surgical Company (NASDAQ: STAA ), ... ophthalmic lenses for refractive surgery, today announced CE Mark ... design.  The V4c design incorporates a proprietary port in ... determined to optimize the flow of fluid within the ...
Cached Medicine Technology:PDI Announces Group DCA's Launch of eDetailing Across Apple® and Android™ Mobile Devices 2Visian® ICL and Toric ICL V4c Receive CE Mark Approval 2Visian® ICL and Toric ICL V4c Receive CE Mark Approval 3Visian® ICL and Toric ICL V4c Receive CE Mark Approval 4
(Date:4/23/2014)... University researchers have developed a way to detect and ... tiny gold particles with tails of synthetic DNA., A ... biological engineering, used gold nanoparticles to target and bind ... RNA splice variants, which can indicate the presence and ... splice variants in a cell can be determined by ...
(Date:4/23/2014)... area of the gastro-intestinal tract has long been considered ... at the Sahlgrenska Academy have used refined microscopic techniques ... inner surface of the gastro-intestinal tract is only as ... Fndriks. , The digestive tract, which passes from the ... has a length of about 5 meters in a ...
(Date:4/23/2014)... and accessible detection methods that can rapidly screen ... a single cell inside that population has been ... Lu. , In the Royal Society of Chemistry ... that he and his coworkers have developed a ... a protein ( Chem. Sci. , 2014, DOI: ...
(Date:4/23/2014)... vegetables are often displayed in the popular Swedish ... plenty of high-sugar foods. A new study from ... portrayed in children,s TV programmes as well as ... habits and weight status. , Steingerdur Olafsdottir,s doctoral ... the popular Swedish children,s TV show Bolibompa. Healthy ...
(Date:4/23/2014)... of scientists led by a researcher from the Cancer ... University of Singapore has identified the cancer specific stem ... the possibility of developing new drugs for the treatment ... The research group, led by Dr Chan Shing Leng, ... first time that a cancer-specific variant of a cell ...
Breaking Medicine News(10 mins):Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:The surface area of the digestive tract 'only' as large as a studio apartment 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3
... and emerging biomedical approaches to HIV/AIDS prevention will be ... sponsored by the UCSF-Gladstone Institute for Virology and Immunology ... for AIDS Prevention Studies. , "Defining new biomedical approaches ... high priority. This symposium will provide a timely ...
... Blue Shield of Michigan supports physical activity and nutrition ... More than 16,600 Michigan children and their local communities ... and other physical activities and to learn to eat ... of Michigan.They,ll join youngsters like those at Detroit,s Maybury ...
... 94 percent BENTONVILLE, Ark., Feb. 13 Wal-Mart Stores, Inc., ... of associates who have health care coverage through its benefits ... percent to 94.5 percent. Over 733,000 or 51.8 percent of ... total - were covered by Wal-Mart,s plans at the end ...
... says the dark kind protects against cancer, along with being ... chocolate to your Valentine might be more than sweet; it ... great news this Valentine,s Day is that in addition to ... play a role in cancer prevention," Sally Scroggs, a health ...
... (Nasdaq:, EMAG ), a leader in enterprise medical ... today that it has received the,$9 million that had ... York Mellon by,Health Systems Solutions, Inc. (OTC Bulletin Board: ... escrowed funds became payable to Emageon,when the merger was ...
... electronic medical records to be provided at locations ... has entered into a clinical collaboration with MinuteClinic, ... care in the United States, at several locations ... which provide a convenient, seven-day-a-week option for those ...
Cached Medicine News:Health News:UCSF symposium considers biomedical approaches to HIV/AIDS prevention 2Health News:Schools Receive Grants to Help Kids be Active, Eat Healthy 2Health News:Schools Receive Grants to Help Kids be Active, Eat Healthy 3Health News:Schools Receive Grants to Help Kids be Active, Eat Healthy 4Health News:Schools Receive Grants to Help Kids be Active, Eat Healthy 5Health News:Schools Receive Grants to Help Kids be Active, Eat Healthy 6Health News:Wal-Mart Health Care Benefits Enrollment Rises, Uninsured Rate Declines 2Health News:Wal-Mart Health Care Benefits Enrollment Rises, Uninsured Rate Declines 3Health News:Chocolate for Your Valentine a Healthy Idea 2Health News:Emageon Receives Escrowed Funds and Terminates Merger Agreement 2Health News:Emageon Receives Escrowed Funds and Terminates Merger Agreement 3Health News:Cleveland Clinic Enters into Agreement with MinuteClinic 2Health News:Cleveland Clinic Enters into Agreement with MinuteClinic 3Health News:Cleveland Clinic Enters into Agreement with MinuteClinic 4
...
...
...
... plate system features an advanced design that ... Trinica system gives surgeons the flexibility to ... anatomy. Flexibility is built-in to every aspect ... the innovative Secure-Twist anti-migration system to the ...
Medicine Products: